rolapitant   Click here for help

GtoPdb Ligand ID: 5749

Synonyms: SCH 619734 | SCH-619734 | Varubi® | Varuby®
Approved drug
rolapitant is an approved drug (FDA (2015), EMA (2017))
Compound class: Synthetic organic
Comment: Rolapitant is an orally available neurokinin-1 (NK1) receptor antagonist.
Rolapitant is example 72b in patents US20110098468 [2] and US7049320 B2 [3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 50.36
Molecular weight 500.19
XLogP 5.24
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C1CCC2(N1)CCC(NC2)(COC(c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C)c1ccccc1
Isomeric SMILES O=C1CC[C@@]2(N1)CC[C@@](NC2)(CO[C@@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C)c1ccccc1
InChI InChI=1S/C25H26F6N2O2/c1-16(17-11-19(24(26,27)28)13-20(12-17)25(29,30)31)35-15-23(18-5-3-2-4-6-18)10-9-22(14-32-23)8-7-21(34)33-22/h2-6,11-13,16,32H,7-10,14-15H2,1H3,(H,33,34)/t16-,22-,23-/m1/s1
InChI Key FIVSJYGQAIEMOC-ZGNKEGEESA-N
No information available.
Summary of Clinical Use Click here for help
Rolapitant is approved to treat chemotherapy-induced nausea and vomiting in combination with other antiemetic agents.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Activation of NK-1 receptors plays a central role in nausea and vomiting induced by certain cancer chemotherapies. Rolapitant antagonises this receptor activation and so reduces symptoms.
External links Click here for help